by In2Pharma | Jan 11, 2023 | News
The Netherlands Marketing authorization holders who want to temporarily supply a medicine in a different packaging in the event of a medicine shortage will need permission from the CBG from 1 January 2023. The CBG will take over this task from the Healthcare and Youth...
by In2Pharma | Dec 12, 2022 | News
The Netherlands Drug shortages are an important issue since the COVID-19 pandemic. According to the Medicines Act, each Marketing Authorisation Holder (MAH) and Wholesaler must ensure that sufficient supply of each medicine is available. The interpretation of...
by In2Pharma | Feb 16, 2022 | News
The Netherlands Medicinal Product Quality Defects and Shortages on the Dutch Market should be reported through the “Meldpunt geneesmiddelentekorten en -defecten”. As of 01 January 2022, the Medicines Evaluation Board (MEB) and the Inspectorate (IGJ) have implemented...
by In2Pharma | Feb 16, 2022 | News
The Netherlands The Medicines Evaluation Board (MEB) increases the fee rates for authorisation applications, authorisation changes and the annual fees of human medicinal products. Fees for consultation procedures will also be increased. Fees for veterinary will remain...
by In2Pharma | Oct 26, 2021 | News
The Netherlands The reporting form of the Medicine Shortages and Defects Reporting Center has been made more user-friendly. Some questions were deleted (e.g. address details of the company), textual changes were done, some questions were added and changes to the...
